|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NOP16 |
Gene summary for NOP16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NOP16 | Gene ID | 51491 |
| Gene name | NOP16 nucleolar protein | |
| Gene Alias | HSPC111 | |
| Cytomap | 5q35.2 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9Y3C1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51491 | NOP16 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.15e-10 | 4.23e-01 | -0.0811 |
| 51491 | NOP16 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.14e-02 | 2.59e-01 | -0.1526 |
| 51491 | NOP16 | HTA11_696_2000001011 | Human | Colorectum | AD | 6.98e-03 | 1.95e-01 | -0.1464 |
| 51491 | NOP16 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.58e-14 | 5.88e-01 | -0.059 |
| 51491 | NOP16 | HTA11_7862_2000001011 | Human | Colorectum | AD | 7.81e-04 | 3.18e-01 | -0.0179 |
| 51491 | NOP16 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.19e-20 | 6.03e-01 | 0.096 |
| 51491 | NOP16 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.19e-06 | 4.72e-01 | 0.0528 |
| 51491 | NOP16 | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.77e-16 | 4.75e-01 | 0.0674 |
| 51491 | NOP16 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.93e-19 | 6.46e-01 | 0.294 |
| 51491 | NOP16 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.17e-03 | 3.12e-01 | 0.281 |
| 51491 | NOP16 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.89e-35 | 8.68e-01 | 0.3859 |
| 51491 | NOP16 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.41e-05 | 4.69e-01 | 0.2585 |
| 51491 | NOP16 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.32e-07 | 2.95e-01 | 0.3005 |
| 51491 | NOP16 | LZE4T | Human | Esophagus | ESCC | 2.08e-07 | -4.53e-02 | 0.0811 |
| 51491 | NOP16 | LZE7T | Human | Esophagus | ESCC | 9.89e-14 | 1.99e-01 | 0.0667 |
| 51491 | NOP16 | LZE20T | Human | Esophagus | ESCC | 1.16e-07 | -1.28e-01 | 0.0662 |
| 51491 | NOP16 | LZE22D1 | Human | Esophagus | HGIN | 1.10e-02 | -3.56e-01 | 0.0595 |
| 51491 | NOP16 | LZE24T | Human | Esophagus | ESCC | 1.32e-05 | 3.37e-01 | 0.0596 |
| 51491 | NOP16 | P1T-E | Human | Esophagus | ESCC | 7.47e-05 | -2.90e-02 | 0.0875 |
| 51491 | NOP16 | P2T-E | Human | Esophagus | ESCC | 3.09e-16 | 3.41e-01 | 0.1177 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613 | Colorectum | AD | ribonucleoprotein complex biogenesis | 151/3918 | 463/18723 | 1.96e-09 | 1.39e-07 | 151 |
| GO:0042273 | Colorectum | AD | ribosomal large subunit biogenesis | 28/3918 | 72/18723 | 3.74e-04 | 4.31e-03 | 28 |
| GO:0042254 | Colorectum | AD | ribosome biogenesis | 84/3918 | 299/18723 | 1.82e-03 | 1.50e-02 | 84 |
| GO:00226131 | Colorectum | SER | ribonucleoprotein complex biogenesis | 112/2897 | 463/18723 | 5.01e-07 | 2.48e-05 | 112 |
| GO:00422731 | Colorectum | SER | ribosomal large subunit biogenesis | 23/2897 | 72/18723 | 3.60e-04 | 5.61e-03 | 23 |
| GO:00422541 | Colorectum | SER | ribosome biogenesis | 66/2897 | 299/18723 | 1.48e-03 | 1.60e-02 | 66 |
| GO:00226132 | Colorectum | MSS | ribonucleoprotein complex biogenesis | 144/3467 | 463/18723 | 2.76e-11 | 3.67e-09 | 144 |
| GO:00422732 | Colorectum | MSS | ribosomal large subunit biogenesis | 28/3467 | 72/18723 | 4.16e-05 | 7.83e-04 | 28 |
| GO:00422542 | Colorectum | MSS | ribosome biogenesis | 79/3467 | 299/18723 | 4.32e-04 | 5.23e-03 | 79 |
| GO:002261327 | Esophagus | HGIN | ribonucleoprotein complex biogenesis | 158/2587 | 463/18723 | 2.61e-29 | 5.23e-26 | 158 |
| GO:004225426 | Esophagus | HGIN | ribosome biogenesis | 101/2587 | 299/18723 | 8.74e-19 | 4.03e-16 | 101 |
| GO:004227326 | Esophagus | HGIN | ribosomal large subunit biogenesis | 34/2587 | 72/18723 | 8.82e-12 | 1.06e-09 | 34 |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:0042273111 | Esophagus | ESCC | ribosomal large subunit biogenesis | 65/8552 | 72/18723 | 1.53e-15 | 9.82e-14 | 65 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:004225412 | Liver | Cirrhotic | ribosome biogenesis | 154/4634 | 299/18723 | 1.18e-23 | 6.72e-21 | 154 |
| GO:004227312 | Liver | Cirrhotic | ribosomal large subunit biogenesis | 47/4634 | 72/18723 | 4.20e-13 | 3.29e-11 | 47 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NOP16 | SNV | Missense_Mutation | novel | c.544N>C | p.Glu182Gln | p.E182Q | Q9Y3C1 | protein_coding | deleterious_low_confidence(0) | benign(0.031) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| NOP16 | SNV | Missense_Mutation | c.438N>T | p.Trp146Cys | p.W146C | Q9Y3C1 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NOP16 | SNV | Missense_Mutation | c.329C>T | p.Thr110Ile | p.T110I | Q9Y3C1 | protein_coding | tolerated(0.14) | possibly_damaging(0.637) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NOP16 | SNV | Missense_Mutation | c.284A>G | p.Asn95Ser | p.N95S | Q9Y3C1 | protein_coding | tolerated(0.1) | benign(0.1) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| NOP16 | insertion | Nonsense_Mutation | novel | c.433_434insTCCAAGGTCCCCAACCTGGCTTCTGGGACTGGT | p.Arg145delinsIleGlnGlyProGlnProGlyPheTrpAspTrpTer | p.R145delinsIQGPQPGFWDW* | Q9Y3C1 | protein_coding | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| NOP16 | deletion | Frame_Shift_Del | novel | c.417delN | p.Leu140PhefsTer27 | p.L140Ffs*27 | Q9Y3C1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| NOP16 | SNV | Missense_Mutation | novel | c.694A>G | p.Met232Val | p.M232V | Q9Y3C1 | protein_coding | tolerated_low_confidence(0.67) | benign(0) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| NOP16 | SNV | Missense_Mutation | novel | c.149N>A | p.Arg50Gln | p.R50Q | Q9Y3C1 | protein_coding | tolerated(0.31) | benign(0.05) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NOP16 | SNV | Missense_Mutation | novel | c.476C>T | p.Ala159Val | p.A159V | Q9Y3C1 | protein_coding | tolerated_low_confidence(0.07) | benign(0.003) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| NOP16 | SNV | Missense_Mutation | rs776470859 | c.602N>A | p.Arg201His | p.R201H | Q9Y3C1 | protein_coding | tolerated_low_confidence(0.25) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |